349 related articles for article (PubMed ID: 31119688)
1. Characteristics of Patients with Type-1 or Type-2 Diabetes Receiving Insulin Glargine U300: An Analysis of 7268 Patients Based on the DPV and DIVE Registries.
van Mark G; Lanzinger S; Sziegoleit S; Putz FJ; Durmaz M; Borscheller M; Danne T; Seufert J; Holl RW; Bramlage P
Adv Ther; 2019 Jul; 36(7):1628-1641. PubMed ID: 31119688
[TBL] [Abstract][Full Text] [Related]
2. [Which patients from routine care use the new insulin analogue glargine U300 compared to patients with glargine U100 : A multicenter analysis of 14,123 patients with insulin glargine from die diabetes registries DPV and DIVE].
Bohn B; Bramlage P; Wagner C; Kaltheuner M; Welp R; Sziegoleit S; Zimmermann A; Reuter HM; Hummel M; Gloyer J; Holl RW; Danne T
Wien Med Wochenschr; 2018 Nov; 168(15-16):415-422. PubMed ID: 28828553
[TBL] [Abstract][Full Text] [Related]
3. Experience after switching from insulin glargine U100 to glargine U300 in patients with type 1 diabetes mellitus. A study after one year of treatment in real life.
Pujante Alarcón P; Rodríguez Escobedo R; García Urruzola F; Ares J; Manjón L; Sanchez Ragnarson C; Cacho L; Delgado E; Menéndez Torre EL
Endocrinol Diabetes Nutr (Engl Ed); 2019 Apr; 66(4):210-216. PubMed ID: 30559088
[TBL] [Abstract][Full Text] [Related]
4. Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus: DosInGlar Study.
Duque N; Artime E; Romera I; Lebrec J; Díaz S; Rubio M; Sicras-Mainar A; Carretero-Anibarro E; Mundet X; Gorgojo-Martínez JJ; Reviriego J
Adv Ther; 2021 Jul; 38(7):3857-3871. PubMed ID: 34052987
[TBL] [Abstract][Full Text] [Related]
5. A Randomized Controlled Trial Comparing Glargine U300 and Glargine U100 for the Inpatient Management of Medicine and Surgery Patients With Type 2 Diabetes: Glargine U300 Hospital Trial.
Pasquel FJ; Lansang MC; Khowaja A; Urrutia MA; Cardona S; Albury B; Galindo RJ; Fayfman M; Davis G; Migdal A; Vellanki P; Peng L; Umpierrez GE
Diabetes Care; 2020 Jun; 43(6):1242-1248. PubMed ID: 32273271
[TBL] [Abstract][Full Text] [Related]
6. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial.
Philis-Tsimikas A; Klonoff DC; Khunti K; Bajaj HS; Leiter LA; Hansen MV; Troelsen LN; Ladelund S; Heller S; Pieber TR;
Diabetologia; 2020 Apr; 63(4):698-710. PubMed ID: 31984443
[TBL] [Abstract][Full Text] [Related]
7. [New generation of insulins: glargine U300. Summary of clinical evidence].
Musso C; Capurro L; Mingote E; Forti L; Guaita MS
Medicina (B Aires); 2019; 79(4):241-250. PubMed ID: 31487242
[TBL] [Abstract][Full Text] [Related]
8. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.
Heise T; Nørskov M; Nosek L; Kaplan K; Famulla S; Haahr HL
Diabetes Obes Metab; 2017 Jul; 19(7):1032-1039. PubMed ID: 28295934
[TBL] [Abstract][Full Text] [Related]
9. Changes in HbA1c and hypoglycemic episodes in type 1 diabetes patients after switching to insulin glargine U300: Pilot study.
Gradišer M; Berković MC; Bilić-Ćurčić I
Diabetes Res Clin Pract; 2017 Jul; 129():144-147. PubMed ID: 28527305
[TBL] [Abstract][Full Text] [Related]
10. Real-world Safety and Effectiveness of Insulin Glargine 300 U/mL in Participants with Type 2 Diabetes Mellitus During the Period of Ramadan in Four Countries (Egypt, Jordan, Lebanon, and Turkey): A Prospective Observational Study.
Hassanein M; Shaltout I; Malek R; Assaad Khalil S; Ballout H; Annabi F; Shereen M
Curr Diabetes Rev; 2024; 20(5):e110823219694. PubMed ID: 37581325
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study.
Pfohl M; Siegmund T; Pscherer S; Pegelow K; Seufert J
Vasc Health Risk Manag; 2015; 11():569-78. PubMed ID: 26604774
[TBL] [Abstract][Full Text] [Related]
12. A multicentre, UK, retrospective, observational study to assess the effectiveness of insulin glargine 300 units/ml in treating people with Type 1 diabetes mellitus in routine clinical practice (SPARTA).
Pang T; Bain SC; Black RNA; Boyle JG; Elliott J; Holcombe A; Lee KCS; Mulligan C; Saunders L; Yousseif A; Baxter M
Diabet Med; 2019 Jan; 36(1):110-119. PubMed ID: 30362181
[TBL] [Abstract][Full Text] [Related]
13. U300, a novel long-acting insulin formulation.
Sutton G; Minguet J; Ferrero C; Bramlage P
Expert Opin Biol Ther; 2014 Dec; 14(12):1849-60. PubMed ID: 25311556
[TBL] [Abstract][Full Text] [Related]
14. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
15. Safety, efficacy, and cost-effectiveness of insulin degludec U100 versus insulin glargine U300 in adults with type 1 diabetes: a systematic review and indirect treatment comparison.
Martin ; Zhou Y; Takagi T; Tian YS
Int J Clin Pharm; 2022 Jun; 44(3):587-598. PubMed ID: 35476308
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the clinical effectiveness and safety of insulin glargine 300 U/mL in individuals with type 2 diabetes uncontrolled on basal insulin: A real-world evidence study from Saudi Arabia (EVOLUTION).
Al Malki F; El Damanhoury B; Othman A; Alghamdi Z; AlQahtani M; Madgy A; Chouikrat Z
Diabetes Obes Metab; 2023 Oct; 25(10):2869-2877. PubMed ID: 37485767
[TBL] [Abstract][Full Text] [Related]
17. New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus.
Goldman J; White JR
Ann Pharmacother; 2015 Oct; 49(10):1153-61. PubMed ID: 26238470
[TBL] [Abstract][Full Text] [Related]
18. Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).
Roussel R; d'Emden MC; Fisher M; Ampudia-Blasco FJ; Stella P; Bizet F; Cali AMG; Wysham CH
Diabetes Obes Metab; 2018 Feb; 20(2):448-452. PubMed ID: 28736942
[TBL] [Abstract][Full Text] [Related]
19. An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin.
Evans M; Billings LK; Håkan-Bloch J; Slothuus U; Abrahamsen TJ; Andersen A; Jansen JP
J Med Econ; 2018 Apr; 21(4):340-347. PubMed ID: 29164973
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria.
Russel-Szymczyk M; Valov V; Savova A; Manova M
BMC Endocr Disord; 2019 Dec; 19(1):132. PubMed ID: 31796048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]